A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

229

Participants

Timeline

Start Date

May 2, 2023

Primary Completion Date

March 25, 2024

Study Completion Date

March 25, 2024

Conditions
Plaque Psoriasis
Interventions
DRUG

DC-806

DC-806 was supplied as tablets to be administered orally.

OTHER

Placebo

Matching placebo was supplied as tablets to be administered orally.

Trial Locations (56)

1085

Semmelweis Egyetem, Budapest

3200

DICE Therapeutics Study Site, Gyöngyös

4103

DICE Therapeutics Study Site, Leipzig

5000

Allergo-Derm Bakos Kft., Szolnok

7400

DICE Therapeutics Study Site, Kaposvár

8200

MedMare Bt, Veszprém

9700

DICE Therapeutics Study Site, Szombathely

10117

DICE Therapeutics Study Site, Berlin

10789

ISA - Interdisciplinary Study Association GmbH, Berlin

23538

DICE Therapeutics Study Site, Lübeck

28026

Hospital Universitario 12 de Octubre, Madrid

35010

Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria

48149

DICE Therapeutics Study Site, Münster

50009

CHUS - H. Clinico U. de Santiago, Santiago de Compostela

53127

DICE Therapeutics Study Site, Bonn

60590

Universitätsklinikum Frankfurt, Frankfurt am Main

72076

DICE Therapeutics Study Site, Tübingen

91054

DICE Therapeutics Study Site, Erlangen

92708-3701

First OC Dermatology, Fountain Valley

90404-2120

Clinical Science Institute, Santa Monica

33134-3901

Driven Research LLC, Coral Gables

34102-6538

Kirsch Dermatology - Probity - PPDS, Naples

33713-8012

GCP Global Clinical Professionals, LLC, St. Petersburg

33613-1244

ForCare Clinical Research - CenExel FCR - PPDS, Tampa

46168-2792

The Indiana Clinical Trials Center, PC, Plainfield

40202-2862

Dermatology Specialists Research - 501 S 2nd St, Louisville

10003-3314

DICE Therapeutics Study Site, New York

45040-4520

Dermatologists of Southwest Ohio - Probity - PPDS, Mason

19103-4738

Paddington Testing Company Inc, Philadelphia

77598-4927

Center for Clinical Studies - Webster, Webster

23502-3945

Virginia Clinical Research Inc, Norfolk

T6G 1C2

Alberta DermaSurgery Centre - Probity - PPDS, Edmonton

V3V 0C6

Enverus Medical Research - Probity - PPDS, Surrey

R3M 3Z4

Wiseman Dermatology Research Inc. - Probity - PPDS, Winnipeg

L1S 7K8

CCA Medical Research - Probity - PPDS, Ajax

L4M 7G1

SimcoDerm Medical and Surgical Dermatology Centre - Probity - PPDS, Barrie

L8N 1Y2

Dermatrials Research, Hamilton

L3P 1X2

Lynderm Research Inc. - Probity - PPDS, Markham

Unknown

DermEdge Research Probity - PPDS, Mississauga

M2M 4J5

DICE Therapeutics Study Site, North York

N2J 1C4

Alliance Clinical Trials - Probity - PPDS, Waterloo

G1V 4X7

Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ), Québec

100 00

Fakultni nemocnice Kralovske Vinohrady - CRC - PPDS, Prague

CCR Prague s.r.o. - PRATIA - PPDS, Prague

130 00

CCR Prague s.r.o. - PRATIA - PPDS, Prague

150 00

DICE Therapeutics Study Site, Prague

50-566

Cityclinic Przychodnia lekarsko psychologiczna Matusiak sp.p, Wroclaw

51-685

Wro Medica, Wroclaw

90-436

Dermoklinika-Centrum Medyczne s.c, Lódz

02-665

Centrum Medyczne Reuma Park NZOZ, Warsaw

35-055

Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie, Rzeszów

15-879

ClinicMed Daniluk, Nowak Spólka Komandytowa, Bialystok

40-611

Centrum Medyczne Angelius Provita, Katowice

70-332

Laser Clinic S.C., Szczecin

L22 0LG

Synexus Merseyside Clinical Research Centre, Liverpool

M23 9QZ

Medicines Evaluation Unit, Manchester

All Listed Sponsors
lead

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

INDUSTRY

NCT05896527 - A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter